

## Effect of Sacubitril/Valsartan on Exercise-Induced Lipid Metabolism in Patients With Obesity and Hypertension

Stefan Engeli, Rudi Stinkens, Tim Heise, Marcus May, Gijs H. Goossens, Ellen E. Blaak, Bas Havekes, Thomas Jax, Diego Albrecht, Parasar Pal, Uwe Tegtbur, Sven Haufe, Thomas H. Langenickel, Jens Jordan

**Abstract**—Sacubitril/valsartan (LCZ696), a novel angiotensin receptor-neprilysin inhibitor, was recently approved for the treatment of heart failure with reduced ejection fraction. Neprilysin degrades several peptides that modulate lipid metabolism, including natriuretic peptides. In this study, we investigated the effects of 8 weeks' treatment with sacubitril/valsartan on whole-body and adipose tissue lipolysis and lipid oxidation during defined physical exercise compared with the metabolically neutral comparator amlodipine. This was a multicenter, randomized, double-blind, active-controlled, parallel-group study enrolling subjects with abdominal obesity and moderate hypertension (mean sitting systolic blood pressure  $\geq 130$ – $180$  mmHg). Lipolysis during rest and exercise was assessed by microdialysis and [1,1,2,3,3- $^2$ H]-glycerol tracer kinetics. Energy expenditure and substrate oxidation were measured simultaneously using indirect calorimetry. Plasma nonesterified fatty acids, glycerol, insulin, glucose, adrenaline and noradrenaline concentrations, blood pressure, and heart rate were also determined. Exercise elevated plasma glycerol, free fatty acids, and interstitial glycerol concentrations and increased the rate of glycerol appearance. However, exercise-induced stimulation of lipolysis was not augmented on sacubitril/valsartan treatment compared with amlodipine treatment. Furthermore, sacubitril/valsartan did not alter energy expenditure and substrate oxidation during exercise compared with amlodipine treatment. In conclusion, sacubitril/valsartan treatment for 8 weeks did not elicit clinically relevant changes in exercise-induced lipolysis or substrate oxidation in obese patients with hypertension, implying that its beneficial cardiovascular effects cannot be explained by changes in lipid metabolism during exercise.

**Clinical Trial Registration**—URL: <https://www.clinicaltrials.gov>. Unique identifier: NCT01631864.

(*Hypertension*. 2018;71:70-77. DOI: 10.1161/HYPERTENSIONAHA.117.10224.) • [Online Data Supplement](#)

**Key Words:** exercise-induced lipolysis ■ hypertension ■ lipid metabolism ■ natriuretic peptide, neprilysin ■ obesity ■ sacubitril/valsartan

Fatty acids are stored in the form of triglycerides in the adipose tissue and are released during lipolysis to fuel lipid oxidation in energy consuming tissues. Lipolysis and skeletal muscle lipid oxidation decrease after carbohydrate ingestion and increase in the fasting state or during physical exercise.<sup>1</sup> An imbalance between fatty acid mobilization and utilization may adversely affect cardiovascular and metabolic health. Acute experimental increases in circulating fatty acids in humans worsened hepatic<sup>2</sup> and skeletal muscle<sup>3</sup> insulin sensitivity and endothelium-mediated vasodilation.<sup>4</sup> Chronic increase in fatty acid availability promotes hepatic, skeletal muscle, myocardial lipotoxicity, dyslipidemia, insulin resistance, and type 2 diabetes mellitus.<sup>5,6</sup> Conversely, interventions that reduce fatty acid levels improve metabolic health.<sup>5</sup> These observations are

highly relevant for cardiovascular medications with the potential to affect lipid turnover.

Sacubitril/valsartan, comprising a novel neprilysin inhibitor prodrug sacubitril and angiotensin receptor blocker (valsartan), has been approved for the treatment of chronic heart failure (HF; NYHA [New York Heart Association] Class II-IV) with reduced ejection fraction.<sup>7</sup> The endopeptidase neprilysin is ubiquitously expressed, including in human adipocytes, and degrades multiple peptides such as natriuretic peptides (NPs), angiotensin II, bradykinin, and endothelin that may modulate lipid metabolism.<sup>8,9</sup> Notably, NPs potentially augment human adipose tissue lipolysis, postprandial lipid oxidation, and skeletal muscle oxidative capacity,<sup>9</sup> whereas angiotensin II elicits more subtle changes in fatty acid turnover.<sup>10</sup> Given the role and association

Received August 23, 2017; first decision September 11, 2017; revision accepted October 18, 2017.

From the Institute of Clinical Pharmacology (S.E., M.M., S.H., J.J.), Institute of Sports Medicine (U.T.), Hannover Medical School, Germany; Department of Human Biology, NUTRIM School of Nutrition and Translational Research in Metabolism (R.S., G.H.G., E.E.B.), Division of Endocrinology, Department of Internal Medicine (B.H.), Maastricht University Medical Center, The Netherlands; Profil, Neuss, Germany (T.H., T.J.); Translational Medicine, Novartis Pharma AG, Basel, Switzerland (D.A., T.H.L.); Biostatistical Sciences, Integrated Development Functions and Regions, Novartis Healthcare Pvt. Ltd, Hyderabad, India (P.P.); and Institute of Aerospace Medicine, German Aerospace Center (DLR) and Chair of Aerospace Medicine, University of Cologne, Germany (J.J.).

The online-only Data Supplement is available with this article at <http://hyper.ahajournals.org/lookup/suppl/doi:10.1161/HYPERTENSIONAHA.117.10224/-DC1>.

Correspondence to Jens Jordan, Institute of Aerospace Medicine, German Aerospace Center, Linder Hoehe, 51147 Cologne, Germany. E-mail jens.jordan@dlr.de

© 2017 The Authors. *Hypertension* is published on behalf of the American Heart Association, Inc., by Wolters Kluwer Health, Inc. This is an open access article under the terms of the [Creative Commons Attribution Non-Commercial-NoDerivs](#) License, which permits use, distribution, and reproduction in any medium, provided that the original work is properly cited, the use is noncommercial, and no modifications or adaptations are made.

*Hypertension* is available at <http://hyper.ahajournals.org>

DOI: 10.1161/HYPERTENSIONAHA.117.10224

of aberrant NP- and renin-angiotensin-aldosterone signaling in cardiovascular diseases and metabolic dysfunction, we hypothesized that simultaneous blockade of angiotensin receptor and neprilysin with sacubitril/valsartan can potentially ameliorate metabolic dysfunction, especially lipid turnover, compared with amlodipine. In the present study, we investigated the effects of 8-week treatment with sacubitril/valsartan compared with the metabolically neutral comparator amlodipine on whole-body and adipose tissue lipolysis, energy expenditure and substrate oxidation during defined physical exercise, which is known to stimulate NP release and induce lipolysis and lipid oxidation.

## Methods

### Study Design

The study design, key inclusion and exclusion criteria of the patients, and the primary results of this study have been described earlier.<sup>11</sup> Briefly, this was a multicenter, randomized, double-blind, double-dummy, active-controlled, parallel-group study enrolling adult subjects with abdominal obesity (waist circumference  $\geq 102$  cm for men and  $\geq 88$  cm for women) and moderate hypertension (mean sitting systolic blood pressure [BP]  $\geq 130$  and  $< 180$  mm Hg). Key exclusion criteria were severe hypertension (mean sitting systolic blood pressure  $\geq 180$  mm Hg), type 1 or 2 diabetes mellitus (fasting plasma glucose  $\geq 126$  mg/dL or HbA1c  $\geq 6.5\%$ ), dyslipidemia requiring therapy with fibrates or nicotinic acid, concomitant use of antihypertensive, antidiabetic or other medications that affect glucose or lipid metabolism, and a history or current diagnosis of HF (NYHA class II-IV).

The study included a screening period of up to 4 weeks followed by a 4-week washout period and an 8-week randomized, double-blind, and double-dummy treatment phase. Patients receiving antihypertensive medications at the time of screening discontinued the therapy during the washout period. During the treatment period, patients were randomized to receive either sacubitril/valsartan 400 mg every day (QD) or amlodipine 10 mg QD along with a matching placebo for 8 weeks. Patients were stratified into 4 groups based on baseline homeostatic model assessment of insulin resistance and statin use.

All patients provided written informed consent before screening. The clinical study protocol was reviewed and approved by the Independent Ethics Committee or Institutional Review Board at each center and, conducted in accordance with the declaration of Helsinki.

### Exercise Test

An incremental exercise test on a bicycle ergometer was conducted before the start of intervention (day -14) to determine the maximal aerobic capacity ( $\text{VO}_2$  peak) at volitional exhaustion by measuring the individual maximum workload before stopping for exhaustion or until predefined heart rate or BP criteria were met. At baseline (day 1) and after 8 weeks (day 57), subjects exercised at 50% of  $\text{VO}_2$  peak (as determined on day -14) for a period of 60 minutes.

### Measurement of Lipolysis

Local adipose tissue and whole-body lipolysis were assessed at baseline and after 8 weeks of treatment as described previously.<sup>11</sup> Local adipose tissue lipolysis was measured by microdialysis and assessed during a 45-minute interval at rest, followed by a 60-minute interval during which the patients exercised at 50% of their individual  $\text{VO}_2$  peak. Dialysates were collected from abdominal subcutaneous adipose at the lower right abdominal quadrant at rest and at 15-minute intervals during exercise. Concentrations of glycerol (as an indicator of lipolysis), glucose, and lactic acid in dialysates were measured. The ethanol outflow/inflow ratio (ratio of ethanol concentration in the dialysate and perfusate) was measured as an indicator of adipose tissue blood flow.

Whole-body lipolysis was estimated using [ $1,1,2,3,3\text{-}^2\text{H}$ ]-glycerol tracer kinetics after an intravenous glycerol bolus ( $2 \mu\text{mol}\cdot\text{kg}^{-1}$ ) after insertion of the microdialysis catheter,  $\approx 60$  minutes before the baseline measurements started, and subsequent infusion at an infusion rate of  $0.1 \mu\text{mol}\cdot\text{kg}^{-1}\cdot\text{min}^{-1}$  at rest and  $0.2 \mu\text{mol}\cdot\text{kg}^{-1}\cdot\text{min}^{-1}$  during

exercise. Blood samples were collected at 15-minute intervals at rest and during exercise. The rate of appearance of endogenous glycerol was calculated as the ratio of glycerol tracer infusion rate:plasma glycerol tracer enrichment. At steady state, glycerol rate of appearance was calculated from glycerol enrichment using Steele equation.

### Energy Expenditure and Substrate Oxidation

Energy expenditure and substrate oxidation during rest and exercise were assessed by indirect calorimetry using a ventilated hood system. The ventilated hood measurements were recorded for 30 minutes in the resting phase with the patient in supine position and during the last 10 minutes of the 60-minute exercise period.

### Circulating Metabolites and Hormones

Samples for fasting plasma biomarkers (nonesterified fatty acid [NEFA], glycerol, glucose, insulin, adrenaline, and noradrenaline) were collected at baseline (day 1) and on day 57 at rest and during exercise concurrently with microdialysis measurements.

### Blood Pressure

Office BP was measured at screening, during washout and throughout the study at baseline, week 4, week 8, and at the end of study using the same arm and the same automated equipment with an appropriate cuff size. Measurements were performed in triplicate at 2-minute intervals after patients had been sitting for 15 minutes with the back supported and both feet on the floor. BP was also measured during the exercise phase. During the home stay period, patients were given a home measurement device and instructed to monitor BP twice weekly at approximately the same time each morning.

### Statistical Analysis

After 8 weeks of treatment with sacubitril/valsartan or amlodipine, assessments of local adipose tissue lipolysis, whole-body lipolysis, oxidative metabolism, BP, and biomarkers during exercise were performed as prespecified study objectives.

For abdominal subcutaneous adipose tissue microdialysate data (ethanol ratio, dialysate lactate, dialysate glucose, and dialysate glycerol), plasma biomarkers (glycerol, NEFA, glucose, insulin, adrenaline, and noradrenaline), and whole-body lipolysis (rate of glycerol appearance) data for 45 minutes at rest and 4 time points during exercise (15, 30, 45, and 60 minutes) were analyzed using repeated measures analysis on log-transformed values with treatment, visit, time, and treatment $\times$ visit $\times$ time interaction as fixed effects. Geometric mean ratios of each exercise time point to 45-minute resting for each day and treatment, ratios of day 57 to day 1 for each treatment and each exercise time point, and the ratio between sacubitril/valsartan and amlodipine for day 57 to day 1 were calculated.

Oxidative metabolism was analyzed using ANCOVA with treatment as the fixed effect and baseline as the covariate. Oxidative metabolism during exercise was analyzed using ANOVA for repeated measurements with treatment, visit, and treatment $\times$ visit interaction as fixed effects. Mean difference to day 1 (day 57 versus day 1) for each treatment along with the corresponding 95% confidence intervals and *P* values are presented. Data for exercise and resting phase were analyzed for each day and treatment with a mixed-effects linear model with phase (exercise or resting) as the fixed effect and subject as the random effect to obtain the mean difference estimate and 95% confidence interval for exercise versus rest comparison. Respiratory quotient ( $\text{CO}_2/\text{O}_2$  ratio) was calculated at each of the days 1 and 57 at rest and during exercise. A statistical comparison of the quotients was then made between rest and exercise within each day.

## Results

### Exercise Testing

On day 1, 39 patients randomized to the sacubitril/valsartan group and 24 patients randomized to the amlodipine group completed the constant workload exercise for 60 minutes. On day 57, 36 patients treated with sacubitril/valsartan and 23

treated with amlodipine completed the exercise for 60 minutes. Similar observations were made in patients completing only 45 and 60 minutes of exercise, suggesting that 8 weeks of treatment of patients with obesity and hypertension with sacubitril/valsartan or amlodipine did not have any clinically relevant impact on the exercise duration. Oxygen consumption and workload were comparable between days 1 and 57 in both treatment groups (Table S1 in the [online-only Data Supplement](#)).

### Plasma Glucose and Insulin Concentrations

With exercise, plasma glucose concentrations increased in the amlodipine group for all time points and for 30 minutes ( $P=0.017$ ), 45 minutes ( $P=0.002$ ), and 60 minutes ( $P<0.001$ ) in the sacubitril/valsartan group on day 1. On day 57, the increase was significant during 60 minutes of exercise in the sacubitril/valsartan group ( $P=0.031$ ) but the increase was not significant at any time point in the amlodipine group. A decrease in glucose levels was noticed on day 57 in both treatment groups as compared with baseline (day 1), with the difference being significant only in the amlodipine group at 30 minutes ( $P=0.017$ ) and 45 minutes ( $P<0.001$ ) of exercise. However, no statistically significant differences in glucose concentrations were observed between the treatment groups at any time point.

A decrease in insulin concentrations with increasing exercise duration was observed in both treatment groups. When compared with resting insulin concentrations, a significant decrease was observed at 45 minutes ( $P=0.015$ ) and 60 minutes ( $P<0.001$ ) on day 1 and at 45 minutes ( $P=0.044$ ) on day 57 in the sacubitril/valsartan group. However, exercise-induced decreases in insulin concentrations were not statistically significant in the amlodipine group, either on day 1 or 57. After 8 weeks of treatment, compared with baseline, insulin concentrations were significantly lower in amlodipine group at all time points except 60 minutes, whereas the change was not significant at any time point in the sacubitril/valsartan group. Significant differences in insulin concentrations were observed at 30 minutes ( $P=0.017$ ) and 45 minutes ( $P=0.027$ ) between the treatment groups on day 57 compared with baseline.

### Subcutaneous Adipose Tissue Lipolysis During Exercise

Compared with resting measurements, microdialysate glycerol concentrations increased during exercise indicating increased subcutaneous adipose tissue lipolysis in both the amlodipine and sacubitril/valsartan groups on days 1 and 57. Compared with baseline, microdialysate glycerol concentrations during exercise were numerically lower in the amlodipine group on day 57. In the sacubitril/valsartan group, microdialysate glycerol concentrations increased similarly at the beginning and at the end of treatment, but this increase was not statistically significant (Figure 1). Microdialysate glucose concentrations were comparable between sacubitril/valsartan and amlodipine at baseline (sacubitril/valsartan versus amlodipine: 15 minutes [1.07 versus 0.94 mmol/L]; 30 minutes [1.06 versus 1.02 mmol/L]; 45 minutes [1.05 versus 0.99 mmol/L]; and 60 minutes [1.03 versus 0.91 mmol/L]) and on day 57 (15 minutes [1.12 versus 0.95 mmol/L]; 30 minutes [1.08 versus 0.94 mmol/L]; 45 minutes [1.07 versus 1.02 mmol/L]; and 60

minutes [1.06 versus 1.01 mmol/L]). No statistically significant differences in glucose levels from baseline to week 8 were observed for any time points in both the treatment groups. No significant differences were observed between the two treatment groups. A similar trend was observed for lactate levels.

Ethanol ratios were comparable between sacubitril/valsartan and amlodipine on day 1 (sacubitril/valsartan versus amlodipine: 15 minutes [0.42 versus 0.43]; 30 minutes [0.42 versus 0.44]; 45 minutes [0.43 versus 0.45]; and 60 minutes [0.47 versus 0.46]). Ethanol ratios increased on day 57 in both the sacubitril/valsartan and amlodipine groups, but remained comparable between treatment groups (15 minutes [0.49 versus 0.49]; 30 minutes [0.51 versus 0.49]; 45 minutes [0.53 versus 0.51]; and 60 minutes [0.55 versus 0.53]). These data suggest that there were no relevant change in blood flow that needs to be accounted for when interpreting glycerol measurements.

### Whole-Body Lipolysis


Plasma glycerol concentrations increased with exercise in both treatment groups, both on days 1 and 57 (amlodipine group, day 1 versus 57: resting [89.77 versus 88.04  $\mu\text{mol/L}$ ]; 15 minutes [141.12 versus 119.56  $\mu\text{mol/L}$ ]; 30 minutes [184.78 versus 156.03  $\mu\text{mol/L}$ ]; 45 minutes [216.04 versus 179.27  $\mu\text{mol/L}$ ]; and 60 minutes [224.85 versus 191.95  $\mu\text{mol/L}$ ]) and sacubitril/valsartan, day 1 versus 57: resting [85.64 versus 83.93  $\mu\text{mol/L}$ ]; 15 minutes [139.3 versus 126.92  $\mu\text{mol/L}$ ]; 30 minutes [177.65 versus 157.29  $\mu\text{mol/L}$ ]; 45 minutes [205.68 versus 189.84  $\mu\text{mol/L}$ ]; and 60 minutes [225.62 versus 205.26  $\mu\text{mol/L}$ ]). Compared with baseline, plasma glycerol levels were lower in both the treatment groups on day 57. Although the change from baseline to day 57 was significant at all time points in the amlodipine group ( $P<0.05$ ), it was significant at 30 minutes in the sacubitril/valsartan group ( $P=0.012$ ). The differences in plasma glycerol levels between treatment groups were not significant.

As compared with glycerol rate of appearance after 45-minute rest, a significant increase was observed during exercise at all time points in both treatment groups on days 1 and 57 ( $P<0.001$ ). The change from baseline to day 57 was statistically significant in the sacubitril/valsartan group at 15 minutes ( $P=0.026$ ), 30 minutes ( $P=0.012$ ), and 45 minutes ( $P=0.035$ ) but was not significant at any time point in the amlodipine group (Figure 2A). However, there was no significant difference between treatment groups at any time point.

Plasma NEFA concentrations decreased on day 57 at 15 minutes in the sacubitril/valsartan group ( $P=0.018$ ) and at 15 and 30 minutes ( $P<0.05$ ) in the amlodipine group. No significant differences were observed between treatment groups. When compared with NEFA levels at rest (for 45 minutes), the levels were lower during the initial phases of exercise, but increased gradually with increasing exercise duration in both treatment groups (Figure 2B).

### Oxidative Metabolism During Exercise

Oxygen consumption was comparable between the sacubitril/valsartan and amlodipine groups at baseline ( $\text{O}_2$  consumption: amlodipine,  $1.31\pm 0.45$  L/min; sacubitril/valsartan,  $1.40\pm 0.41$  L/min) and on day 57 (amlodipine,  $1.27\pm 0.39$  L/min; sacubitril/valsartan,  $1.37\pm 0.44$  L/min) and no differences were found between treatment groups.



**Figure 1.** Comparison of local adipose tissue lipolysis (dialysate glycerol) variable during exercise following 8 weeks of treatment with sacubitril/valsartan and amlodipine. Error bars indicate 95% confidence interval. † $P=0.003$  vs baseline.

The respiratory quotient significantly increased during exercise in both the treatment groups, on days 1 and 57 (Figure 3). The respiratory quotient was comparable between treatments at baseline and on day 57.

### Plasma Catecholamine Concentrations

When compared with resting levels, adrenaline levels increased significantly during exercise at all time points in both treatment groups on days 1 and 57 (Figure 4A). Compared with baseline, a significant reduction in adrenaline levels were observed on day 57 in the amlodipine groups at all time points, whereas the decrease was not statistically significant in the sacubitril/valsartan group. However, no significant differences were observed in the adrenaline levels between treatment groups at any time point, except at 30 minutes ( $P=0.012$ ).

Plasma noradrenaline levels were significantly increased during exercise in both the treatment groups on days 1 and 57 ( $P<0.001$ ) when compared with resting levels (Figure 4B). Noradrenaline levels increased incrementally during exercise on days 1 and 57 in both the treatment groups, with no significant differences between treatments.

### Blood Pressure

After 8 weeks of treatment, systolic BP, diastolic BP, and pulse pressure decreased from baseline in both treatment groups at rest. Systolic and diastolic BP and pulse rate values increased during exercise in both treatment groups on both days 1 and 57 without clinically relevant differences between treatment groups (Table).


### Discussion

The present study demonstrated that treatment with sacubitril/valsartan compared with amlodipine for 8 weeks did not elicit relevant changes in exercise-induced lipolysis and substrate oxidation in obese patients with hypertension. The exercise-induced increase in abdominal subcutaneous adipose tissue

and whole-body lipolysis was not augmented after sacubitril/valsartan treatment compared with amlodipine treatment. Moreover, the shift in substrate oxidation toward carbohydrate catabolism during exercise was comparable in both treatment groups, implying that sacubitril/valsartan did not significantly affect lipid utilization during acute exercise. We have previously observed significantly improved whole-body insulin sensitivity and a modest increase in resting abdominal subcutaneous lipolysis, with no marked changes in whole-body lipolysis, with sacubitril/valsartan compared with amlodipine treatment.<sup>11</sup> Overall, these findings imply that the beneficial cardiometabolic effects of sacubitril/valsartan may not be explained by changes in lipid mobilization or oxidation.

In this study, we used state-of-the-art methodology including [1,1,2,3,3-<sup>2</sup>H]-glycerol tracer kinetics and abdominal subcutaneous adipose tissue microdialysis to assess whole-body and local lipolysis, respectively, in a large patient sample. Furthermore, we treated patients with a total daily dose of sacubitril/valsartan which provided superior BP control in patients with arterial hypertension (400 mg QD)<sup>12</sup> and reduced cardiovascular mortality and HF hospitalizations in patients with HF and reduced ejection fraction (200 mg twice daily) compared with standard of care renin-angiotensin system inhibition.<sup>7</sup> This study, therefore, was appropriately designed to study the effect of sacubitril/valsartan on lipid turnover.

Our study extends previous investigations on the role of neprilysin substrates and angiotensin II type 1 ( $AT_1$ )-receptors in the regulation of lipid turnover. All components of the renin-angiotensin system are expressed in adipose tissue, and  $AT_1$ -receptors have been implicated in the regulation of adipose tissue differentiation, inflammation, and metabolism.<sup>10</sup> Conflicting findings have been reported with respect to the effects of angiotensin II on adipose tissue lipolysis. More specifically, both increased<sup>13,14</sup> and decreased<sup>15</sup> subcutaneous adipose tissue lipolysis have been demonstrated.<sup>14</sup> Moreover,




**Figure 2.** Whole-body lipolysis during exercise: comparison of rate of glycerol appearance between treatments (A) and plasma concentration of nonesterified fatty acid (NEFA; B). Error bars indicate 95% confidence interval. † $P=0.026$ , \* $P=0.012$ , ‡ $P=0.035$  vs baseline; \*\* $P=0.002$ , \*\*\* $P<0.001$  vs 45 minutes of rest.


intravenous angiotensin II infusions and angiotensin-converting enzyme inhibition did not elicit major changes in whole-body lipolysis as determined by glycerol tracer kinetics.<sup>16</sup> AT<sub>1</sub>-receptor blockade in humans did not increase lipolytic gene expression or lipolysis in abdominal subcutaneous adipose

tissue.<sup>17,18</sup> However, long-term AT<sub>1</sub>-receptor blockade altered intramuscular lipid partitioning, manifested by decreased saturation of skeletal muscle triacylglycerol and diacylglycerol stores, reduced postprandial fatty acid spillover and lipolysis.<sup>19</sup> Overall, angiotensin II actions on AT<sub>1</sub>-receptors seems to have modest effects on lipid turnover. Although postprandial fatty acid handling has not been examined in this study, the present findings suggest that AT<sub>1</sub>-receptor blockade in the context of neprilysin inhibition by sacubitril/valsartan does not have clinically relevant effects on lipid mobilization or utilization.

Neprilysin degrades multiple peptides that potentially modulate lipid metabolism such as NPs, bradykinin, endothelin-1, and glucagon-like peptide 1.<sup>20</sup> While bradykinin has been suggested to attenuate lipolysis, endothelin-1 may increase lipolysis. However, endothelin-1 was significantly decreased after treatment of patients with HF and reduced ejection fraction with sacubitril/valsartan for 21 days, and no changes in lipolysis for glucagon-like peptide 1 at high concentrations have been reported.<sup>21–25</sup> As the results of this study present the net effect of sacubitril/valsartan, we cannot discern contributions of individual neprilysin substrates to the observed metabolic response nor can we rule out that opposite effects of individual neprilysin substrates result in an overall negative



**Figure 3.** Oxidative metabolism: comparison of respiratory quotient between resting and exercise status, carbon dioxide:oxygen ratio. Error bars indicate 95% confidence interval. \*\*\* $P<0.01$ , exercise versus rest.



**Figure 4.** Analysis of plasma biomarkers during exercise: adrenaline (A) and noradrenaline (B). Error bars indicate 95% confidence interval. † $P=0.044$ , †† $P=0.022$ , ††† $P=0.019$ , \*\* $P<0.001$  vs baseline; <sup>a</sup> $P=0.012$  vs amlodipine.

effect. Among neprilysin substrates, lipolytic effects of NPs are particularly striking. In *ex vivo* experiments with human adipocytes, NPs were substantially more potent in stimulating lipolysis than the prototypical  $\beta$ -adrenoreceptor agonist isoproterenol with comparable efficacy.<sup>26</sup> In *in vivo*, atrial NP infusion in physiologically relevant doses potently stimulates adipose tissue lipolysis.<sup>27</sup> This increase in adipose tissue lipolysis is not attenuated with systemic  $\beta$ -adrenoreceptor blockade.<sup>28</sup> Because NP-induced lipolysis is observed only in primates, the utility of many preclinical animal models is limited.<sup>29</sup> NPs are released during physical exercise and may provide lipid fuel to the working skeletal muscle, which is generally considered beneficial. Excess NP-mediated lipid mobilization has been suggested as a potential limitation of therapeutic neprilysin inhibition if associated with increased NEFA plasma concentrations; however, this was not observed after treatment with sacubitril/valsartan in the present study. Furthermore, the lack of changes in exercise-induced lipolysis by sacubitril/valsartan observed in the present study is clinically reassuring as *ex vivo* lipolysis of subcutaneous adipose tissue was not desensitized in patients with HF despite increased circulating NP levels.<sup>30</sup>

Given the potent acute effect of NPs on human lipolysis, our findings are somewhat unexpected. Plasma noradrenaline and adrenaline increased to a similar extent at baseline and after treatment with amlodipine and sacubitril/valsartan, suggesting that opposing changes in sympathoadrenal activity did

not mask a direct treatment effect on lipolysis. The reduction in catecholamine levels observed with sacubitril/valsartan in this study is consistent with our previous observation.<sup>11</sup> Conflicting observations have been reported with respect to the effect of amlodipine therapy on noradrenaline levels,<sup>31–33</sup> whereas valsartan treatment has been demonstrated to attenuate increases in plasma noradrenaline concentrations with larger reductions from baseline associated with lower risk of mortality and morbidity.<sup>34,35</sup> Although sacubitril/valsartan improved insulin-mediated glucose disposal compared with amlodipine,<sup>11</sup> potential antilipolytic effects of insulin in adipose tissue after sacubitril/valsartan have not been investigated before. We cannot completely rule out that improved insulin action in adipose tissue confounded our analysis. However, an alternative and more likely explanation is that NP actions in adipose tissue are not, or to a lesser degree, dependent on neprilysin activity. Indeed, a study in isolated human adipocytes suggests that clearance via the NP receptor C, the so-called scavenger receptor, may be more important than neprilysin activity to control local NP availability.<sup>36</sup> Indeed, completely abolishing neprilysin activity using thiorphan did not modify atrial NP-mediated lipolysis.<sup>36</sup>

Noteworthy, we conducted our study in obese patients with hypertension. Given the differences in neurohormonal activity between patients with hypertension and HF, the extent to which our findings can be applied to patients with HF and reduced ejection fraction remains to be elucidated. However, a recent post hoc

**Table. Comparison of BP and Pulse Rate Between Treatments During Exercise and Rest**

BP/Pulse Rate	Day/Visit	Exercise/Rest	Sacubitril/Valsartan 400 mg QD (n=50)	Amlodipine 10 mg QD (n=48)
SBP, mmHg	Day 1	Rest	137.9±14.67	135.8±12.82
		Exercise	157.5±23.77	146.5±23.3
	Day 57	Rest	119.9±14.28	125.9±10.23
		Exercise	146.8±21.89	137.6±20.49
DBP, mmHg	Day 1	Resting	88.0±10.65	86.8±8.89
		Exercise	82.8±12.57	84.3±12.39
	Day 57	Resting	77.2±8.49	81.2±7.19
		Exercise	78.4±12.33	78.8±11.98
Pulse rate, bpm	Day 1	Resting	67.4±8.6	66.7±9.28
		Exercise	121.2±15.40	111.4±25.62
	Day 57	Resting	65.2±8.70	69.2±10.48
		Exercise	123.5±18.62	115.6±16.54

Data are mean±SD. BP indicates blood pressure; bpm, beats per minute; DBP, diastolic BP; QD, every day; SBP, systolic BP; and SD, standard deviation.

analysis of the PARADIGM-HF trial (Prospective Comparison of Angiotensin Receptor Neprilysin Inhibitor With Angiotensin-Converting Enzyme Inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure) showed that in patients with HF and type 2 diabetes mellitus, treatment with sacubitril/valsartan resulted in greater reductions in HbA1c levels compared with those treated with enalapril. Moreover, sacubitril/valsartan treated patients with type 2 diabetes mellitus were less likely to require initiation of insulin treatment during the trial suggesting potential metabolic benefits of sacubitril/valsartan therapy in HF patients.<sup>37</sup> Another potential limitation of the study is that we ascertained the effect of sacubitril/valsartan therapy on only exercise-induced lipolysis, which is one of the strong physiological stimuli regulating lipolysis. However, it remains to be elucidated whether the findings of our study can be extrapolated to other physiological circuits affecting lipid mobilization from adipose tissue, such as fasting or postprandial responses. Finally, the selection of amlodipine as a metabolically neutral comparator does not allow distinguishing the contributions of neprilysin inhibition from those of AT<sub>1</sub>-receptor blockade to the effects of sacubitril/valsartan observed in this study.

### Perspectives

Aberrant renin-angiotensin system activation and NP signaling are not only common in cardiovascular diseases, but are also implicated in metabolic dysfunction. Hence, there is a growing need to recognize the potential metabolic actions of cardiovascular pharmacotherapies, especially those targeting renin-angiotensin system and NP systems. Our study demonstrated that sacubitril/valsartan treatment did not result in clinically relevant changes in exercise-induced abdominal subcutaneous adipose tissue and whole-body lipolysis, energy expenditure and substrate oxidation compared with amlodipine. This finding is relevant because neprilysin substrates, particularly NPs, have been implicated in lipolysis and the pathogenesis of cardiac cachexia. Although the extent to

which the present findings can be extrapolated to patients with HF and reduced ejection fraction remains to be elucidated, the lack of changes in exercise-induced lipolysis by sacubitril/valsartan is clinically reassuring. Our findings further support the idea that neprilysin is of lesser importance in regulating NP availability in the vicinity of adipocytes.

### Acknowledgments

We acknowledge Nagabhushana Ananthamurthy, Rohan Mitra, and Sreedevi Boggarapu (Scientific Services, Novartis Healthcare Pvt Ltd, Hyderabad) for providing medical writing and editorial support.

### Sources of Funding

This study was funded by Novartis Pharma AG, Basel, Switzerland.

### Disclosures

S. Engeli has received significant financial support to conduct clinical studies from Novartis and Boehringer-Ingelheim, and modest lecture fees from Pfizer. T. Heise reports speaker honoraria and travel grants from Eli Lilly, Mylan and Novo Nordisk, honoraria for advisory panels from Novo Nordisk; and through Profil received research funds from Adocia, Astra Zeneca, Becton Dickinson, Biocon, Boehringer-Ingelheim, Dance Pharmaceuticals, Eli Lilly, Grünenthal, Gulf Pharmaceuticals, Johnson & Johnson, Marvel, Medimmune, Medtronic, Novartis, Novo Nordisk, Roche Diagnostics, Sanofi, Senseonics, and Zealand Pharma. J. Jordan served as consultant for Novartis, Boehringer-Ingelheim, Sanofi, Orexigen, Riemser, and Vivus; and is cofounder of Eternigen GmbH. D. Albrecht, P. Pal, and T.H. Langenickel are employees of Novartis. The other authors report no conflicts.

### References

1. Spriet LL. New insights into the interaction of carbohydrate and fat metabolism during exercise. *Sports Med*. 2014;44 suppl 1:S87–S96. doi: 10.1007/s40279-014-0154-1.
2. Bevilacqua S, Bonadonna R, Buzzigoli G, Boni C, Ciociaro D, Maccari F, Giorico MA, Ferrannini E. Acute elevation of free fatty acid levels leads to hepatic insulin resistance in obese subjects. *Metabolism*. 1987;36:502–506.
3. Roden M, Price TB, Perseghin G, Petersen KF, Rothman DL, Cline GW, Shulman GI. Mechanism of free fatty acid-induced insulin resistance in humans. *J Clin Invest*. 1996;97:2859–2865. doi: 10.1172/JCI118742.
4. Steinberg HO, Tarshoby M, Monestel R, Hook G, Cronin J, Johnson A, Bayazeed B, Baron AD. Elevated circulating free fatty acid levels impair endothelium-dependent vasodilation. *J Clin Invest*. 1997;100:1230–1239. doi: 10.1172/JCI119636.
5. Shulman GI. Ectopic fat in insulin resistance, dyslipidemia, and cardio-metabolic disease. *N Engl J Med*. 2014;371:2237–2238. doi: 10.1056/NEJMc1412427.
6. Stinkens R, Goossens GH, Jocken JW, Blaak EE. Targeting fatty acid metabolism to improve glucose metabolism. *Obes Rev*. 2015;16:715–757. doi: 10.1111/obr.12298.
7. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR: PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. *N Engl J Med*. 2014;371:993–1004. doi: 10.1056/NEJMoa1409077.
8. Schling P, Schäfer T. Human adipose tissue cells keep tight control on the angiotensin II levels in their vicinity. *J Biol Chem*. 2002;277:48066–48075. doi: 10.1074/jbc.M204058200.
9. Moro C. Natriuretic peptides and fat metabolism. *Curr Opin Clin Nutr Metab Care*. 2013;16:645–649. doi: 10.1097/MCO.0b013e32836510ed.
10. Goossens GH. The renin-angiotensin system in the pathophysiology of type 2 diabetes. *Obes Facts*. 2012;5:611–624. doi: 10.1159/000342776.
11. Jordan J, Stinkens R, Jax T, Engeli S, Blaak EE, May M, Havekes B, Schindler C, Albrecht D, Pal P, Heise T, Goossens GH, Langenickel TH. Improved insulin sensitivity with angiotensin receptor neprilysin inhibition in individuals with obesity and hypertension. *Clin Pharmacol Ther*. 2017;101:254–263. doi: 10.1002/cpt.455.
12. Kario K, Sun N, Chiang FT, Supasyndh O, Baek SH, Inubushi-Molessa A, Zhang Y, Gotou H, Lefkowitz M, Zhang J. Efficacy and safety of

- LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Asian patients with hypertension: a randomized, double-blind, placebo-controlled study. *Hypertension*. 2014;63:698–705. doi: 10.1161/HYPERTENSIONAHA.113.02002.
13. Boschmann M, Adams F, Schaller K, Franke G, Sharma AM, Klaus S, Luft FC, Jordan J. Hemodynamic and metabolic responses to interstitial angiotensin II in normal weight and obese men. *J Hypertens*. 2006;24:1165–1171. doi: 10.1097/01.hjh.0000226207.11184.5f.
  14. Boschmann M, Jordan J, Adams F, Christensen NJ, Tank J, Franke G, Stoffels M, Sharma AM, Luft FC, Klaus S. Tissue-specific response to interstitial angiotensin II in humans. *Hypertension*. 2003;41:37–41.
  15. Goossens GH, Blaak EE, Saris WH, van Baak MA. Angiotensin II-induced effects on adipose and skeletal muscle tissue blood flow and lipolysis in normal-weight and obese subjects. *J Clin Endocrinol Metab*. 2004;89:2690–2696. doi: 10.1210/jc.2003-032053.
  16. Townsend RR. The effects of angiotensin-II on lipolysis in humans. *Metabolism*. 2001;50:468–472. doi: 10.1053/meta.2001.21021.
  17. Goossens GH, Moors CC, van der Zijl NJ, Venticlef N, Alili R, Jocken JW, Essers Y, Cleutjens JP, Clément K, Diamant M, Blaak EE. Valsartan improves adipose tissue function in humans with impaired glucose metabolism: a randomized placebo-controlled double-blind trial. *PLoS One*. 2012;7:e39930. doi: 10.1371/journal.pone.0039930.
  18. Wang TJ, Larson MG, Keyes MJ, Levy D, Benjamin EJ, Vasan RS. Association of plasma natriuretic peptide levels with metabolic risk factors in ambulatory individuals. *Circulation*. 2007;115:1345–1353. doi: 10.1161/CIRCULATIONAHA.106.655142.
  19. Moors CC, Blaak EE, van der Zijl NJ, Diamant M, Goossens GH. The effects of long-term valsartan treatment on skeletal muscle fatty acid handling in humans with impaired glucose metabolism. *J Clin Endocrinol Metab*. 2013;98:E891–E896. doi: 10.1210/jc.2012-4067.
  20. Mangiafico S, Costello-Boerrigter LC, Andersen IA, Cataliotti A, Burnett JC Jr. Neutral endopeptidase inhibition and the natriuretic peptide system: an evolving strategy in cardiovascular therapeutics. *Eur Heart J*. 2013;34:886–893c. doi: 10.1093/eurheartj/ehs262.
  21. Kobalava Z, Kotovskaya Y, Averkov O, Pavlikova E, Moiseev V, Albrecht D, Chandra P, Ayalamosayajula S, Prescott MF, Pal P, Langenickel TH, Jordaan P, Rajman I. Pharmacodynamic and pharmacokinetic profiles of sacubitril/valsartan (LCZ696) in patients with heart failure and reduced ejection fraction. *Cardiovasc Ther*. 2016;34:191–198. doi: 10.1111/1755-5922.12183.
  22. Eriksson AK, van Harmelen V, Stenson BM, Aström G, Wåhlén K, Laurencikienė J, Rydén M. Endothelin-1 stimulates human adipocyte lipolysis through the ET A receptor. *Int J Obes (Lond)*. 2009;33:67–74. doi: 10.1038/ijo.2008.212.
  23. Mori MA, Sales VM, Motta FL, et al. Kinin b1 receptor in adipocytes regulates glucose tolerance and predisposition to obesity. *PLoS One*. 2012;7:e44782.
  24. Bertin E, Arner P, Bolinder J, Hagström-Toft E. Action of glucagon and glucagon-like peptide-1-(7-36) amide on lipolysis in human subcutaneous adipose tissue and skeletal muscle in vivo. *J Clin Endocrinol Metab*. 2001;86:1229–1234. doi: 10.1210/jcem.86.3.7330.
  25. Villanueva-Peñacarrillo ML, Márquez L, González N, Díaz-Miguel M, Valverde I. Effect of GLP-1 on lipid metabolism in human adipocytes. *Horm Metab Res*. 2001;33:73–77.
  26. Sengenès C, Berlan M, De Glisezinski I, Lafontan M, Galitzky J. Natriuretic peptides: a new lipolytic pathway in human adipocytes. *FASEB J*. 2000;14:1345–1351.
  27. Birkenfeld AL, Boschmann M, Moro C, Adams F, Heusser K, Franke G, Berlan M, Luft FC, Lafontan M, Jordan J. Lipid mobilization with physiological atrial natriuretic peptide concentrations in humans. *J Clin Endocrinol Metab*. 2005;90:3622–3628. doi: 10.1210/jc.2004-1953.
  28. Birkenfeld AL, Boschmann M, Moro C, Adams F, Heusser K, Tank J, Diedrich A, Schroeder C, Franke G, Berlan M, Luft FC, Lafontan M, Jordan J. Beta-adrenergic and atrial natriuretic peptide interactions on human cardiovascular and metabolic regulation. *J Clin Endocrinol Metab*. 2006;91:5069–5075. doi: 10.1210/jc.2006-1084.
  29. Sengenès C, Zakaroff-Girard A, Moulin A, Berlan M, Bouloumié A, Lafontan M, Galitzky J. Natriuretic peptide-dependent lipolysis in fat cells is a primate specificity. *Am J Physiol Regul Integr Comp Physiol*. 2002;283:R257–R265. doi: 10.1152/ajpregu.00453.2001.
  30. Birkenfeld AL, Adams F, Schroeder C, Engeli S, Jordan J. Metabolic actions could confound advantageous effects of combined angiotensin II receptor and neprilysin inhibition. *Hypertension*. 2011;57:e4–e5. doi: 10.1161/HYPERTENSIONAHA.110.165159.
  31. Toal CB, Meredith PA, Elliott HL. Long-acting dihydropyridine calcium-channel blockers and sympathetic nervous system activity in hypertension: a literature review comparing amlodipine and nifedipine GITS. *Blood Press*. 2012;21 suppl 1:3–10. doi: 10.3109/08037051.2012.690615.
  32. Stankovic S, Panz V, Klug E, Di Nicola G, Joffe BI. Amlodipine and physiological responses to brisk exercise in healthy subjects. *Cardiovasc Drugs Ther*. 1999;13:513–517.
  33. de Champlain J, Karas M, Assouline L, Nadeau R, LeBlanc AR, Dubé B, Laroche P. Effects of valsartan or amlodipine alone or in combination on plasma catecholamine levels at rest and during standing in hypertensive patients. *J Clin Hypertens (Greenwich)*. 2007;9:168–178.
  34. Latini R, Masson S, Anand I, Judd D, Maggioni AP, Chiang YT, Bevilacqua M, Salio M, Cardano P, Dunselman PH, Holwerda NJ, Tognoni G, Cohn JN; Valsartan Heart Failure Trial Investigators. Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure: the Valsartan Heart Failure Trial (Val-HeFT). *Circulation*. 2002;106:2454–2458. doi: 10.1161/01.CIR.0000036747.68104.AC.
  35. Anand IS, Fisher LD, Chiang YT, Latini R, Masson S, Maggioni AP, Glazer RD, Tognoni G, Cohn JN; Val-HeFT Investigators. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). *Circulation*. 2003;107:1278–1283. doi: 10.1161/01.CIR.0000054164.99881.00.
  36. Moro C, Klimcakova E, Lafontan M, Berlan M, Galitzky J. Phosphodiesterase-5A and neutral endopeptidase activities in human adipocytes do not control atrial natriuretic peptide-mediated lipolysis. *Br J Pharmacol*. 2007;152:1102–1110. doi: 10.1038/sj.bjp.0707485.
  37. Seferovic JP, Claggett B, Seidelmann SB, Seely EW, Packer M, Zile MR, Rouleau JL, Swedberg K, Lefkowitz M, Shi VC, Desai AS, McMurray JJV, Solomon SD. Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial. *Lancet Diabetes Endocrinol*. 2017;5:333–340. doi: 10.1016/S2213-8587(17)30087-6.

## Novelty and Significance

### What Is New?

- Sacubitril/valsartan treatment did not elicit clinically relevant changes in exercise-induced lipolysis or substrate oxidation in obese patients with hypertension.

### What Is Relevant?

- An imbalance between fatty acid mobilization and utilization may adversely affect cardiovascular and metabolic health.
- Natriuretic peptides potentially augment human adipose tissue lipolysis, postprandial lipid oxidation, and skeletal muscle oxidative capacity, whereas angiotensin II elicits more subtle changes in fatty acid turnover.
- Natriuretic peptides are released during physical exercise and have been suggested to provide lipid fuel to the working skeletal muscle. However, excess natriuretic peptide-mediated lipolysis and its implications in car-

diac cachexia have been suggested as potential limitations of neprilysin inhibition. Therefore, the lack of changes in exercise-induced lipolysis by sacubitril/valsartan is clinically reassuring.

- Our study extends previous investigations on the role of neprilysin substrates and angiotensin II type 1 receptors in the regulation of lipid turnover.

### Summary

Treatment with sacubitril/valsartan did not elicit clinically relevant changes in exercise-induced lipolysis, energy expenditure, and substrate oxidation in patients with obesity and hypertension compared with amlodipine. These observations further substantiate the hypothesis that neprilysin is of lesser importance in regulating natriuretic peptide availability in the vicinity of adipocytes.